Prime Medicine (PRME) Cash from Operations (2021 - 2026)
Prime Medicine posted quarterly Cash from Operations of 42710000.0 for Q1 2026, up 12.58% year-on-year from 37936922.22 in Q1 2025, and down 14.64% on a QoQ basis from 37256000.0 in Q4 2025.
Prime Medicine (PRME) has 6 years of Cash from Operations data on file, last reported at 42710000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 12.58% year-over-year to 42710000.0; the trailing twelve-month figure through Mar 2026 stood at 156417000.0 (down 50.38% YoY), and the FY2025 full-year result was 162564000.0, down 32.31% from the prior year.
- Cash from Operations for Q1 2026 stood at 42710000.0, down from 37256000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 16245000.0 in Q4 2024 and bottomed at 67707000.0 in Q1 2024.
- The 5-year median for Cash from Operations is 40821000.0 (2023), against an average of 36786941.18.
- The widest annual swing landed in 2024, when Cash from Operations surged 137.03%; it then slumped 329.34% in 2025.
- A 5-year view of Cash from Operations shows it stood at 30713000.0 in 2022, then tumbled by 42.82% to 43864000.0 in 2023, then soared by 137.03% to 16245000.0 in 2024, then slumped by 329.34% to 37256000.0 in 2025, then decreased by 14.64% to 42710000.0 in 2026.
- The last three Cash from Operations figures came in at 42710000.0 (Q1 2026), 37256000.0 (Q4 2025), and 35039000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -42.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.71 Mn |
| Mar 31, 2026 | -42.71 Mn |
| Dec 31, 2025 | -37.26 Mn |
| Dec 31, 2025 | -37.26 Mn |
| Sep 30, 2025 | -35.04 Mn |
| Sep 30, 2025 | -35.04 Mn |
| Jun 30, 2025 | -41.41 Mn |
| Jun 30, 2025 | -41.41 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Sep 30, 2024 | -25.91 Mn |
| Sep 30, 2024 | -25.91 Mn |
| Jun 30, 2024 | -45.49 Mn |
| Jun 30, 2024 | -45.49 Mn |
| Mar 31, 2024 | -67.71 Mn |
| Mar 31, 2024 | -67.71 Mn |
| Dec 31, 2023 | -43.86 Mn |
| Dec 31, 2023 | -43.86 Mn |
| Sep 30, 2023 | -39.17 Mn |
| Sep 30, 2023 | -39.17 Mn |
| Jun 30, 2023 | -40.82 Mn |
| Jun 30, 2023 | -40.82 Mn |
| Mar 31, 2023 | -41.56 Mn |
| Mar 31, 2023 | -41.56 Mn |
| Dec 31, 2022 | -30.71 Mn |
| Dec 31, 2022 | -30.71 Mn |
| Sep 30, 2022 | -30.10 Mn |
| Sep 30, 2022 | -30.10 Mn |
| Jun 30, 2022 | -20.22 Mn |
| Jun 30, 2022 | -20.22 Mn |
| Mar 31, 2022 | -50.79 Mn |
| Mar 31, 2022 | -50.79 Mn |
| Dec 31, 2021 | -13.19 Mn |
| Dec 31, 2021 | -13.19 Mn |